NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...
First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, ...
According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback